Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026

Cincinnati Children’s Applied Gene and Cell Therapy Center selected to conduct tech transfer, development and IND-enabling manufacturingAll activities other than long-term stability testing planned to be complete in Q3 2026 to support potential IND filing in Q4 2026Selection of tech transfer partner follows Tempest’s recent announcement of positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003, including 100% CR in all six efficacy evaluable patients, and accelerated development timel ...